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 A study was undertaken to determine whether BCG vaccin tion of cattle post-26 
challenge could have an effect on a very early Mycobacterium bovis infection. Three 27 
groups of calves (n=12/group) were challenged endobronchially with M. bovis and 28 
slaughtered 13 weeks later to examine for tuberculous lesions. One group had been 29 
vaccinated prophylactically with BCG Danish vaccine 21 weeks prior to challenge; a 30 
second group was vaccinated with a 4-fold higher dose f BCG Danish 3 weeks post-31 
challenge and the third group, remained non-vaccinated. Vaccination prior to challenge 32 
induced only minimal protection with just a significant reduction in the lymph node 33 
lesion scores. Compared to the non-vaccinated group, BCG vaccination post-challenge 34 
produced no reduction in gross pathology and histopathology, but did result in significant 35 
increases in mRNA expression of pro-inflammatory mediators (IFN-γ, IL-12p40, IL-17A, 36 
IRF-5, CXCL9, CXCL10, iNOs, and TNF-α) in the pulmonary lymph nodes. Although 37 
there was no significant differences in the gross pathology and histopathology between 38 
the post-challenge BCG and non-vaccinated groups, the enhanced pro-inflammatory 39 
immune responses observed in the post-challenge BCG group suggest caution in the use 40 
of high doses of BCG where there is a possibility that cattle may be infected with M. 41 
bovis prior to vaccination.   42 
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1. Introduction 48 
 Bovine tuberculosis (TB) caused predominantly by M cobacterium bovis poses 49 
significant economic hardship to livestock farmers as well as constituting a public health 50 
problem. It is estimated that >50 million cattle worldwide are infected with M. bovis, 51 
costing US$3 billion annually [1]. Although, the implementation of “test and slaughter” 52 
control programmes has resulted in bovine TB being eradicated from a number of 53 
countries [2], these measures have been less effective in countries which have wildlife 54 
reservoirs of M. bovis infection or where these programmes are not economically or 55 
socially acceptable.  There is renewed interest in he use of TB vaccines for cattle 56 
stemming from the realisation of the financial impact of bovine TB on animal health and 57 
trade and also due to the difficulty of controlling the disease.  Currently, there are no TB 58 
vaccines licenced for use in cattle, although the human TB vaccine, bacille Calmette-59 
Guérin M. bovis (BCG) vaccine has been shown to induce significant levels of protection 60 
in cattle in experimental challenge and field trials (reviewed in [1,3]).  61 
 The major caveats which have restricted BCG being used in cattle until now have 62 
been that vaccination sensitises animals to respond in routine TB diagnostic tests, 63 
particularly in the first year after vaccination [4,5] and protection may not be complete 64 
[1,3]. Research has recently shown that the problem of BCG vaccination compromising 65 
conventional bovine TB diagnostic tests can be overcome by using tests which 66 
differentiate infected from vaccinated animals (DIVA tests), utilising specific 67 
mycobacterial antigens which are expressed by M. bovis, but not by BCG [6,7]. 68 
Secondly, protection can be enhanced by revaccinating with BCG when immunity has 69 
waned [8] or priming cattle with BCG and boosting with a sub-unit vaccine [9]. 70 
Registration of BCG vaccine for cattle will require extensive testing in the field as well as 71 
an assurance of safety for use of BCG vaccine in cattle, including the effect of 72 
vaccination of animals with a pre-existing M. bovis infection. 73 
 The effect of administration of mycobacterial preparations on an existing M. bovis 74 
infection in cattle is not documented, although insights can be gained from studies in 75 
humans and small animal models. Studies by Koch in t e late 19th century revealed that 76 
immunisation of humans with a strong immunogen such as “old tuberculin”, a glycerin 77 















leading to severe toxicities and worsening of the disease, a reaction now known as the 79 
“Koch phenomenon” [10]. Further, it is established that vaccination of humans or small 80 
animal models with BCG does not have a therapeutic effect on an existing M. 81 
tuberculosis infection [11,12], but a question remains whether BCG vaccine, could 82 
exacerbate an existing mycobacterial infection. It has been proposed that BCG 83 
vaccination of immunocompetent M. tuberculosis-infected individuals may result in 84 
increased reactogenicity and morbidity in latently-infected persons (Koch phenomenon) 85 
[13,14].  86 
 A dose of lyophilised BCG Danish vaccine, equivalent to five human doses (1-4 X 87 
106 colony forming units, CFU), has commonly been used in TB vaccine efficacy trials 88 
for cattle, [9,15], although a 10-fold lower dose i still protective [16]. The aim of the 89 
current study was principally to test for the safety of administering a relatively high dose 90 
of BCG to cattle with a pre-existing M. bovis infection and a 4-fold variation in viable 91 
bacilli can be contained in a commercial human BCG vaccine dose (BCG Danish, Statens 92 
Serum institute, Copenhagen, Denmark). One group of cattle were vaccinated with the 93 
standard cattle dose of BCG at 21 weeks prior to challenge with M. bovis and a second 94 
group were vaccinated with a 4-fold higher dose of BCG vaccine at 3 weeks after 95 

















2. Materials & methods 99 
 100 
2.1.  Animals  101 
 Thirty-six Friesian-cross, male-castrated calves, 5-6 months old were obtained from 102 
herds which were accredited as TB-free for the previous 5 years and from an area of New 103 
Zealand where both farmed and feral animals were fre  of TB.  Prior to the studies, the 104 
cattle tested negative for bovine TB in the whole blood IFN-γ test. The cattle were grazed 105 
on pasture in a biocontainment unit. 106 
 107 
2.2 . Bacterial strains and vaccines   108 
 The lyophilised M. bovis BCG Danish 1331 vaccine (Statens Serum Institute, 109 
Copenhagen, Denmark) formulated for humans was utilised to vaccinate the calves. M. 110 
bovis WAg202, originally isolated from a tuberculous possum in New Zealand, was used 111 
as the challenge strain and had been used in previous accination/challenge studies in 112 
cattle [17,18]. Bacteria were grown to mid-log phase in Tween albumin broth (Dubos 113 
broth base, Difco Laboratories, Detroit, Mich.) supplemented with 0.006% (vol/vol) 114 
alkalinised oleic acid, 0.5% (wt/vol) albumin fraction V and 0.25% (wt/vol) glucose. 115 
Dilutions were made in Tween albumin broth to obtain the dose for inoculation.  The 116 
number of CFU inoculated was determined retrospectiv ly by plating 10-fold dilutions on 117 
Middlebrook 7H11 (Difco) supplemented with 0.5% (wt/vol) albumin, 0.2% (wt/vol) 118 
glucose and 1% (wt/vol) sodium pyruvate. 119 
 120 
2.3  Vaccination and M. bovis challenge   121 
 The calves were divided into three groups, each containing 12 calves using a 122 
randomised stratified sampling system so that all groups contained animals with a similar 123 
distribution of IFN-γ responses to avian purified protein derivative (PPD; prepared from a 124 
M. avium culture) in the weeks prior to the start of the study.  Calves from one group 125 
(BCG-vaccinated group) were each vaccinated subcutaneously in the left side of the neck 126 
with 0.5 ml of BCG vaccine (equivalent to 1.5 X 106 CFU/dose, with the other two 127 
groups remaining non-vaccinated. Each vial of BCG vaccine was reconstituted in 1 ml 128 
Sauton medium (Statens Serum Institute) and contained a  estimated 2-8 X 106 CFU/vial, 129 















calves were challenged endobronchially with 5 X 103 CFU of virulent M. bovis as 131 
previously described [17] at 21 weeks after vaccinatio .  Three weeks after the M. bovis 132 
challenge, calves in one of the previously non-vaccinated groups (Post-challenge BCG 133 
group) were each vaccinated subcutaneously in the left side of the neck with 2 ml of BCG 134 
vaccine (6 X 106 CFU; contents of two vaccine vials) The remaining group was named 135 
the Non-vaccinated group. 136 
 137 
2.4. Necropsy procedure   138 
 All cattle were killed 13 weeks after challenge.  Procedures for identifying 139 
macroscopic tuberculous lesions and processing for histopathology have been described 140 
previously [16].  A lung lesion score was calculated by counting the total number of 141 
lesions and applying a score as follows: 0, no lesions; 1, 1-9 lesions; 2, 10-29 lesions; 3, 142 
30-99 lesions; 4, 100-199 lesions; 5, ≥ 200 lesions.  A total lymph node lesion score per 143 
animal was calculated by pooling scores for four major pulmonary lymph nodes (left 144 
bronchial and right bronchial/tracheobronchial and anterior and posterior mediastinal).  145 
Scores for individual lymph nodes were: 0, no lesion ; 1, 1-19 small lesions (1-3 mm 146 
diameter); 2, ≥ 20 small lesions or medium size lesion (4-6 mm diameter); 3, large lesion 147 
(>6 mm).  Samples from four pulmonary lymph nodes were collected from all of the 148 
animals for histology and bacterial culture. Additional samples were collected from any 149 
tuberculous-like lesions observed in lungs, other lymph nodes or organs. For histological 150 
examination, sections were stained with hematoxylin a d eosin. Scoring of 151 
histopathological lesions for the four pulmonary lymph nodes was based on the scale of 152 
stage I to IV granulomas as described by Wangoo et al. [19]. Briefly, stage I granulomas 153 
were composed of accumulations of epitheloid macrophages with low numbers of 154 
lymphocytes, neutrophils and Langhans multinucleated giant cells and there was an 155 
absence of necrosis. Stage II granulomas were similar to stage I granulomas but also had 156 
central infiltrates of neutrophils and lymphocytes and necrosis could be present. Stage III 157 
granulomas exhibited complete fibrous encapsulation and significant necrosis and 158 
mineralisation could be present. Stage IV granulomas were characterised by multiple 159 
coalescing caseo-necrotic granulomas with multicentric ecrosis and mineralisation.  The 160 
percentage of the granulomas classified as Stage I, II, III or IV was calculated from the 161 
total number of granulomas for each group. Scoring of gross and histopathological 162 















culture, tissue samples (2-3 g) were homogenised in a Tenbroeck grinder (Wheaton, 164 
Millville N.J.), decontaminated in 0.75% cetylpyridinium chloride for 1 h, centrifuged at 165 
3500 g for 20 min (included in the decontamination time) and processed for isolation of 166 
mycobacteria as described previously [17]. The CFU/g for each of the four pulmonary 167 
lymph nodes was determined and when no M. bovis was isolated from a sample, a value 168 
of half the minimal count was applied (5 CFU/sample) as not all the sample was cultured. 169 
The value for each animal was the mean of the log10 CFU/g of tissue for the four lymph 170 
nodes and the mean for the group calculated from these values. To measure cytokine 171 
mRNA expression, a small tissue sample from the left bronchial lymph node was 172 
collected from each animal and stored in RNAlater® (Life Technologies, USA). In the 173 
absence of a lesion in this lymph node, but if a lesion was identified in another pulmonary 174 
lymph node, the other lymph node was selected, otherwis  a sample from the non-175 
lesioned left bronchial node was selected.  176 
 177 
2.5. IFN-γ assay  178 
 Heparinised blood samples were collected from the calves at regular intervals to 179 
analyse cellular immune responses. Blood samples (1.5 ml) were dispersed into wells of a 180 
24-well plate and preservative-free bovine PPD prepar d from a M. bovis culture or avian 181 
PPD (24 µg/ml final concentration; Prionics, Schlieren-Zurich, Switzerland) or 182 
phosphate-buffered saline (PBS, negative control) was added. Blood cultures were set up 183 
within 6 hours following blood collection. After incubation at 37oC for 24 h, the plasma 184 
supernatants were harvested and their IFN-γ levels measured using a sandwich ELISA kit 185 
(Mabtech, Sweden). Results were reported as optical density units 450 nm (OD450) for 186 
bovine or avian PPD minus OD450 for PBS.  187 
 188 
2.6.  Tuberculin skin test   189 
 The comparative cervical tuberculin skin test was undertaken at 10 weeks post-190 
challenge. For this test, cattle were inoculated intradermally with 0.1 ml volumes 191 
containing either 3,000 IU of bovine PPD or 2,500 international units (IU) of avian PPD 192 
(Prionics, Lelystad, The Netherlands) at separate sites on the right side of the neck. The 193 
skin-fold thickness was measured with callipers prior to injection and 72 h after injection 194 
of the PPDs. 195 















2.7.  Reverse-transcription and qPCR  197 
 RNA was extracted from lymph node samples, purified and transcribed to cDNA as 198 
previously described [20]. All cDNA samples were stored at −20°C until the qRT-199 
PCRwas undertaken. The primer sequences for IFN-γ, IL-10, IL-12p40, IL-17A, 200 
interferon releasing factor-5 (IRF-5), iNOs and TNF-α were described by Shu et al. [21]. 201 
The forward and reverse primers for IL-2 were AACGGTGCACCTACTTCAAGCTCT 202 
and TAGCGTTAACCTTGGGCGCGTAAA, respectively, while the corresponding 203 
primers for CXCL9 were ACTGGAGTTCAAGGAGTTCCAGCA and 204 
TCTCACAAGAAGGGCTTGGAGCAA and those for CXCL10 were 205 
TCCTCGAACACGGAAAGAGGCATA and AGCTGATATGGTGACTGGCTTGT.  206 
For the qRT-PCR analysis, 10 µl of SyBrPremix Ex Taq II master mixture (Takara 207 
Bio Inc., Japan), 2 µl of template cDNA and 1 µl of 5 µM of each gene-specific primers 208 
were combined in a 20 µl reaction mixture in duplicate. The amplification was performed 209 
in a Rotor-Gene 6000 machine (Corbett Research, Australia). The cycle number at which 210 
the various transcripts became detectable was referred to as the threshold cycle (Ct) and 211 
data were analysed using Rotor-gene 6000 series software 7.0. The average Ct value of 212 
duplicates was used for calculation of the relative fold changes using the ∆∆Ct method 213 
[22]. A previous study showed that the Ct values of the PCR with three house-keeping 214 
genes, GAPDH, β-actin and U1 were consistent within each gene and U1 showed the 215 
lowest Ct value [21]. We used U1 as the house keeping gene for normalisation and the 216 
∆Ct from a pool of non-lesioned, prescapular lymph nodes from M. bovis-infected cattle 217 
sourced from a previous study [21] was used as the calibrator to generate ∆∆Ct. 218 
 219 
2.8.  Statistical analyses   220 
 For analysis of IFN-γ responses a mixed effects model was applied to natural log-221 
transformed IFN-γ responses; time, group and their interaction were fixed effects, and 222 
animal and challenge (an indication variable for identifying before or after challenge) 223 
were random effects. The Kruskal-Wallis test with multiple comparisons was used for 224 
analysing lesion scores and qPCR data. Multiple comparisons of the different groups 225 
were performed with a p-value adjusted by the ‘BH’ method [23]. These analyses were 226 
undertaken using the R packages ‘nlme’, ‘lme4’ and ‘predictmeans’ in R 3.2.0 [24]. The 227 
χ
2 test was used for comparing the distribution of the different granulomas stages for each 228 















lymph node lesions. For the remaining data, statistical analyses were undertaken using 230 
Minitab 16. The mean skin test values, numbers of lesioned lymph nodes/animal and M. 231 
bovis culture positive lymph nodes/animal as well as the mean log10 CFU/g from lymph 232 
nodes were compared using ANOVA with Tukey’s multiple comparisons. Statistical 233 
















3. Results 236 
  237 
3.1.  Pathological and microbiological findings following M. bovis challenge 238 
 Vaccination of calves with BCG prior to M. bovis challenge (BCG-vaccinated 239 
group) produced a significant degree of protection against the challenge in one gross 240 
pathology parameter, with a lower median lymph node lesion score in the BCG-241 
vaccinated group compared to those for the Non-vaccin ted group (P <0.05, Figure 1A). 242 
In addition, BCG vaccination prior to challenge resulted significant reductions in the 243 
proportions of animals with lymph node and lung lesion , lower median lymph node and 244 
lung lesion scores and lower mean number of lesioned lymph nodes per animal compared 245 
to those for the Post-challenge BCG group (Table 1 and Figure 1A and B; P < 0.05). 246 
There were no significant differences between the gross pathology parameters for the 247 
Post-challenge BCG and Non-vaccinated groups. The lesions were typical of those for 248 
bovine TB with multiple small (1-3 mm in diameter) calcified lesions in the lung and 249 
variable sized calcified lesions in the pulmonary lymph nodes (1-20 mm in diameter).  250 
The number of animals in the BCG-vaccinated, Post-challenge BCG and Non-vaccinated 251 
groups with gross tuberculous lesions were 7, 12 and 10, respectively.  No gross 252 
tuberculous lesions were observed outside of the pulmonary cavity. 253 
 Following histopathological examination, a comparison of the relative distribution 254 
of granuloma developmental stages was undertaken. This analysis revealed that the 255 
distribution of granuloma stages was significantly unequal between the three groups 256 
(Figure 2; P = 0.0145, χ2 test).  This was characterized by higher percentags of the most 257 
severe lesions (Stage IV) in the Post-challenge BCG and Non-vaccinated groups, and 258 
lower proportions of the less severe Stage 2 granulomata, compared to those for the 259 
BCG-vaccinated group of calves.  The BCG-vaccinated n  Non-vaccinated groups of 260 
animals had significantly lower mean numbers of pulmonary lymph nodes culture 261 
positive for M. bovis and lower mean log10 CFU of M. bovis/g of pulmonary lymph node 262 
than those for the Post-challenge BCG group (P <0.05, Table 1). No significant 263 
differences were detected between the BCG-vaccinated and Non-vaccinated groups. 264 
 No vaccination site reactions were observed following BCG vaccination in the 265 
Post-challenge BCG group. 266 
 267 















 The kinetics of T cell responses to M. bovis antigens were determined by measuring 269 
the release of IFN-γ from whole blood stimulated with bovine PPD (Figure 3A). 270 
Vaccination with BCG at the commencement of the study resulted in a significant 271 
increase in antigen-specific IFN-γ responses at 3, 6, 8, 10, 12 and 21 weeks after 272 
vaccination compared to the Non-vaccinated group (P < 0.05). Following challenge with 273 
M. bovis at 21 weeks post-vaccination, the mean IFN-γ responses for all groups 274 
increased, with the mean responses for the BCG-vaccin ted and Post-challenge BCG 275 
groups significantly greater than that for the Non-vaccinated group at 3 weeks post-276 
challenge (P < 0.05).  The mean IFN-γ response for the Post-challenge BCG group was 277 
not boosted following vaccination with BCG at 3 weeks after challenge. 278 
 Although all the groups had a similar distribution f IFN-γ responses to avian PPD 279 
at 3 weeks prior to the start of the study, the mean r sponses for the Post-challenge BCG 280 
group were greater than those for the Non-vaccinated group at six of the seven time-281 
points prior to challenge, although none of these diff rences were statistically significant 282 
(Figure 3B). In the period prior to challenge, there was a cumulative increase in the IFN-γ 283 
responses to both avian and bovine PPD in the Post-challenge BCG and Non-vaccinated 284 
groups which suggested exposure to environmental mycobacteria with the animals 285 
grazing on pasture.  286 
 287 
3.3.  Skin test responses after challenge 288 
 At 10 weeks after challenge with M. bovis, all animals with the exception of one 289 
animal from the Non-vaccinated group showed an increase in the skin fold thickness of > 290 
1 mm at 72 hours following injection of bovine PPD. The only significant difference 291 
between the mean skin test responses was that the mean bovine PPD response for the 292 
Post-challenge BCG group (23.3 mm increase in skin fold thickness) was greater than 293 
that for the Non-vaccinated group (mean of 16.0 mm; Table 2; P < 0.05). 294 
 295 
3.4.  mRNA expression of immune mediators from pulmonary lymph nodes post-296 
challenge 297 
Tissue samples were collected from a pulmonary lymph node from each animal 298 
following slaughter of the animals 13 weeks after challenge to measure mRNA 299 
expression of immune mediators by qRT-PCR. Samples were preferentially selected from 300 















mediators are shown in Figure 4. The mean gene expression for IFN-γ, IRF-5, IL-12p40, 302 
IL-17A, iNOs, CXCL9, CXCL10 and TNF-α were significantly greater for the Post-303 
challenge BCG group than those for the Non-vaccinated group (P < 0.05). In addition, the 304 
mean mRNA expression for IFN-γ, CXCL9 and CXCL10 were significantly greater for 305 
the Post-challenge BCG group than those for the BCG-vaccinated group (P < 0.05). No 306 
significant differences were detected between the groups for IL-2 and IL-10 mRNA 307 
expression, or between the BCG-vaccinated and Non-vaccinated groups for any of the 308 

















4.  Discussion 312 
 There is increasing interest in the use of BCG vaccine to protect cattle against 313 
bovine TB, although it is recognized that similar to the situation in humans, BCG does 314 
not provide complete protection against TB at a population or individual animal level.  In 315 
this study, a very stringent test was chosen to answer the question whether vaccinating 316 
infected cattle with BCG would modulate disease outc me. Cattle were vaccinated with a 317 
high dose of BCG only 3 weeks after a relatively high dose experimental challenge with 318 
M. bovis. Three weeks post-challenge is considered as an early stage of a M. bovis 319 
infection for cattle [25]. The dose of lyophilised BCG Danish vaccine most commonly 320 
administered subcutaneously to cattle in TB vaccine efficacy trials has been 0.05 to 0.5 321 
ml (1-4 X 105 to 1-4 X 106 CFU/dose) [8,9,16] and for the current study, the 0.5 ml dose 322 
was chosen for immunisation prior to challenge. In the current study, this dose of BCG 323 
administered prior to challenge induced only minimal protection against TB with a 324 
significant lower median lymph node lesion score compared to the Non-vaccinated 325 
group. Marked variations in the efficacy of BCG vaccination have been previously 326 
reported for protection of cattle against experimental challenge with M. bovis, varying 327 
from a significant reduction in a single pathological or microbiological disease parameter 328 
[18] to a reduction in up to six parameters in a subsequent study [16]. The reasons for this 329 
variation are not clear, although prior sensitisation to environmental mycobacteria has 330 
been considered as a possible explanation for poor responses to BCG vaccination in cattle 331 
[26].  332 
 A 4-fold higher dose of BCG was chosen to vaccinate a group of previously non-333 
vaccinated calves (Post-challenge BCG group) at 3 weeks post-challenge to test for safety 334 
due to the potential variation in the bacterial count that may be present in commercial 335 
BCG vaccines.. There was no significant difference in the gross pathology for the Post-336 
challenge BCG and Non-vaccinated groups and both of these groups had a high 337 
percentage of the more advanced Stage IV granulomata compared to the pre-challenge 338 
BCG group. However, results from the mRNA expression of immune mediators indicated 339 
that there was a more severe inflammatory response at the site of infection in the 340 
pulmonary lymph nodes of the Post-challenge group compared to that for the Non-341 
vaccinated group. qRT-PCR measurement of mRNA expression for eight of the 10 342 















was significantly greater than those for the Non-vaccinated group. Although, the colony 344 
counts of M. bovis in these lymph nodes were significant greater for the Post-challenge 345 
BCG group compared to that for Non-vaccinated group, the bacterial culture method did 346 
not allow virulent M. bovis to be differentiated from BCG. It is possible that BCG bacilli 347 
may have colonised the pulmonary lymph nodes in the Post-challenge BCG animals, 348 
contributing to the higher M. bovis counts.  349 
 Despite the limited availability of safety data for BCG vaccination of humans in 350 
high burden settings, no serious effects were report d following primary vaccination of 351 
tuberculin skin test positive persons in a large India  trial [11]. Furthermore, BCG 352 
revaccination of latently infected adults with prior infant BCG vaccination was also 353 
shown to be safe and reactogenicity similar to thatfor primary BCG vaccination [27]. 354 
However, there are major differences in these trials compared to the current study. In the 355 
human TB trials, the infections were only defined as possible M. tuberculosis infections 356 
based on tuberculin skin test reactivity with the lik lihood of non-specific mycobacterial 357 
or latent M. tuberculosis infections. In contrast, the M. bovis infection in the cattle 358 
resulted in a rapid development of tuberculous lesions in the non-vaccinated animals. It 359 
also needs to be stressed that the post-challenge vaccination took place very early after a 360 
severe M. bovis challenge at the height of the development of anti-tuberculous, cellular 361 
immune responses. Despite these severe experimental conditions, the post-challenge 362 
BCG did not lead to significant increase in gross and microscopic pathology. 363 
 A study in deer demonstrated that subcutaneous vaccination with 5 X 104 and 5 X 364 
107 CFU of BCG Pasteur induced comparable levels of prtection against infection and 365 
disease following intratonsillar challenge with M. bovis, [28].  In contrast, vaccination 366 
with a higher dose of 5 X 108 CFU of BCG Pasteur did not induce protection and evok d 367 
immune responses with a bias towards Type 2 rather than Type 1 reactivity.  In the 368 
current study, there was no boosting of the whole blood antigen-specific IFN-γ responses 369 
following BCG vaccination for the Post-challenge BCG group. This may have been in 370 
part due to the enhanced reactivity to avian PPD antige s for this group in the period 371 
prior to challenge, resulting in a marked increase immediately post-challenge, masking 372 
any subsequent increase in the immune response following BCG vaccination. In 373 
comparison, vaccination with BCG prior to challenge (BCG-vaccinated group) using a 4-374 















response in the period, 3 to 21 weeks post-vaccination. The stronger tuberculin skin test 376 
response observed in the Post-challenge BCG group cmpared to that for the Non-377 
vaccinated group was indicative of a stronger inflammatory response, possibly as a 378 
consequence of an enhanced reactogenicity following BCG vaccination post-challenge. 379 
 Studies in mice have provided information on possible detrimental effects of 380 
administering BCG following infection with M. tuberculosis. Although, BCG vaccination 381 
of mice prior to challenge with M. tuberculosis was protective, BCG vaccination of 382 
already infected mice did not improve the course of infection and repeated revaccination 383 
resulted in an exacerbation of the granulomatous response [12,29]. One of these studies 384 
showed that the increase in the lung tissue damage w s associated with an increase in IL-385 
17, TNF-α, IL-6 and MIP-2 expression and influx of granulocytes/neutrophils [12]. A 386 
pathological role for IL-17 was indicated as this re ponse was abrogated in mice deficient 387 
in the gene encoding IL-23p19 or in the presence of IL-17 blocking antibody. In a further 388 
study, a single subcutaneous administration of liveBCG to mice infected with M. 389 
tuberculosis increased antigen-specific T-cell proliferation and induced larger 390 
tuberculous lung granulomas, but did not induce a rduction in the bacterial load [30]. 391 
The authors suggested that an increased production of TNF-α resulting from vaccination 392 
post-challenge contributed to the increased inflammtion in the lungs and accelerated 393 
death.  394 
 It has been reported that following a mycobacterial infection, an equilibrium is 395 
established between mycobacteria and the host throug  the interaction of mycobacteria 396 
and macrophages in granulomas, maintained by the releas  of immune mediators [31]. 397 
Vaccination after challenge may disturb this equilibrium causing a heightened immune 398 
response in the lesions, particularly when the vaccine is administered at the height of anti-399 
M. bovis effector immune response. Administration of a high dose BCG vaccine to calves 400 
only 3 weeks after the M. bovis challenge induced a pro-inflammatory immune respone 401 
in the pulmonary lymph nodes at 13 weeks post-challenge. There was a significantly 402 
higher expression of IFN-γ, IRF-5, IL-12p40, IL-17A, , iNOs, CXCL9, CXCL10 and 403 
TNF-α compared to that for the Non-vaccinated group, although only the responses to 404 
IFN-γ, CXCL9 and CXCL10 were also higher in this group compared to the animals 405 
vaccinated with BCG before challenge. The sequence of vents is likely to have been 406 















cytokines, which up-regulates expression of IL-6, IL-12, IL-17, IL-23, TNF-α, CXCL10 408 
and type 1 IFNs [32]. Subsequent production of IFN-γ induces the production of 409 
chemokines, CXCL9 and CXCL10, attracting more T lymphocytes and monocytes into 410 
the granulomas [33,34]. Expression of IL-10, the anti-inflammatory cytokine which 411 
inhibits the activity of Th1 cells, NK cells and macrophages [35], was not significantly 412 
increased in the pulmonary lymph nodes of the Post-challenge BCG group. Although, 413 
pro-inflammatory cytokines play an important role in control of mycobacterial infections, 414 
the timing and balance of the cytokines will influenc  whether these responses support 415 
















5. Conclusion  418 
 A very stringent test was used to determine the eff ct of administering BCG 419 
vaccine post-challenge, with cattle vaccinated with a igh dose of BCG only 3 weeks 420 
after experimental infection with M. bovis. Compared to the Non-vaccinated group, 421 
vaccination with BCG post-challenge did not lead to pr tection or, alternatively, to a 422 
significant increase in gross and histo-pathology, although there was an up-regulation of 423 
an array of pro-inflammatory immune mediators from pulmonary lymph node tissues 424 
samples. The strong systemic IFN-γ responses to avian PPD observed in the Post-425 
challenge BCG group prior to challenge may have contributed to the enhanced pro-426 
inflammatory immune responses in the pulmonary lymph nodes of these animals 427 
following challenge and BCG vaccination. However, it does suggest caution in the use of 428 
high doses of BCG vaccine for cattle, where there is a possibility that animals may be 429 
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Table 1. Gross pathological and microbiological findings after Mycobacterium bovis 546 
challenge.  547 
Group 




Mean ±SEM no. 




log10 CFU of M. 





















































PLN Pulmonary lymph node (pulmonary lymph nodes were the only lymph nodes with 548 
gross tuberculous lesions)* Significantly less than those for the Post-challenge BCG and 549 
Non-vaccinated groups (P < 0.05) 550 
















Table 2. Mean (± SEM) skin test responses for cattle at 10 weeks after Mycobacterium 553 
bovis challenge. 554 

































Figure 1. Lesion scores from the lymph nodes (A) and lung (B) for the BCG-vaccinated 557 
group (n=12); Post-challenge BCG group (n=12) and the Non-vaccinated group (n=12) 558 
after the M. bovis challenge. Total lymph node lesion score per animal: score for 559 
individual node: 0, no lesions; 1, 1-19 small lesion  (1-3 mm diameter); 2, ≥ 20 small 560 
lesions or medium size lesion (4-6 mm diameter); 3, large lesion (>6 mm diameter), total 561 
lesion scores for four pulmonary lymph nodes pooled. Lung lesion score: 0, no lesions; 1, 562 
1-9 lesions; 2, 10-29 lesions; 3, 30-99 lesions; 4, 100-199 lesions; 5, ≥ 200 lesions. 563 
Median indicated by horizontal line. Significant difference between groups, * P < 0.05, 564 
** P < 0.01.  565 
Figure 2. Percentages of the different granuloma stages in pulmonary lymph nodes of the 566 
BCG-vaccinated, Post-challenge BCG and Non-vaccinated groups. The histopathological 567 
granulomata stages (I, II, III and IV) are described in the Material and Methods. In total, 568 
383, 952 and 391 granulomata were included in the analysis from BCG vaccinated, Post-569 
challenge BCG treated and Non- vaccinated animals, respectively.  570 
Figure 3. Mean IFN-γ responses following vaccination with BCG and M. bovis 571 
challenge. Figure 3 shows mean IFN-γ responses to bovine PPD (A) and avian PPD (B) 572 
from blood cultures reported as optical density units 450 nm (OD450). BCG-vaccinated 573 
group (, n=12); Post-challenge BCG group (, n=12) and the Non-vaccinated group 574 
(, n=12). Arrow V1 (Week 0) indicates vaccination for the BCG-vaccinated group; 575 
arrow C (Week 21) indicates M. bovis challenge for all groups; arrow V2 (Week 24) 576 
indicates vaccination for Post-challenge BCG group. Error bar represents SEM. Group 577 
mean was significant difference to that for the Non-vaccinated group was indicated by *, 578 
P < 0.05, with analyses performed on natural log-transformed data.  579 
Figure 4. Relative mRNA expression of IFN-γ, IL-12p40, IL-2, CXCL9, IL-10, IRF-5, 580 
IL-17A, TNF-α, IL-10, CXCL10 and iNOs from pulmonary lymph nodes of the BCG-581 
vaccinated group (BCG, n=12); Post-challenge BCG group (PC-BCG, n=12) and the 582 
Non-vaccinated group (NV, n=12).  Target Ct values w re normalised to U1 and a pool of 583 
non-lesioned prescapular lymph nodes was used as calibrator.  The results were presented 584 
as relative fold change of mRNA in a box and whisker plot, with median shown as a 585 






































































































































Figure 4. 598 
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